farnesol has been researched along with Nerve Sheath Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barkan, B; Cox, AD; Kloog, Y | 1 |
| Barkan, B; Friedman, E; Kloog, Y; Starinsky, S; Stein, R | 1 |
2 other study(ies) available for farnesol and Nerve Sheath Neoplasms
| Article | Year |
|---|---|
Ras inhibition boosts galectin-7 at the expense of galectin-1 to sensitize cells to apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Growth Processes; Farnesol; Galactosides; Galectin 1; Galectins; Humans; Nerve Sheath Neoplasms; Neurofibromin 1; ras Proteins; Salicylates; Transcription, Genetic | 2013 |
The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
Topics: Animals; Antineoplastic Agents; Cell Adhesion; Cell Proliferation; Cytoskeleton; Drug Evaluation; Farnesol; Genes, Neurofibromatosis 1; Genes, ras; Humans; Male; Mice; Mice, Nude; Mutation; Nerve Sheath Neoplasms; Neurofibromatosis 1; Neurofibromin 1; ras Proteins; Salicylates; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |